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1. Introduction
1.1. Adipose tissue: The Good, the Bad, the Ugly
Excessive body fat has been socially recognized for ages as a symbol of wealth and prosperity.
Clues of these concepts may be found in arts and literature. In addition, it has been substantially
ignored by scientists, anatomists and physicians for many centuries. As a matter of fact only
a minimal number of medical reports focused on “fat” have been historically handed down.
Nowadays, however, adipose tissue has become a growing point of most interest for research‐
ers and physicians worldwide. Notably, societies and health care systems are facing a severe
pandemic rise of obesity and of several associated co-morbidities such as cardiovascular
disease, diabetes, metabolic disorders and cancer. Fat and misregulation of adipose-related
pathways are recognized as key elements in each of these processes. Importantly, the role of
adipose tissue has progressively evolved from being a passive energy store to representing an
important endocrine organ that directly modulates metabolism and immunity towards an
healthy phenotype or leading to pathologic processes. The investigation of the physiologic-
pathologic attitudes of adipose tissue is currently among most relevant scientific targets of
researchers, endocrinologists and bariatric surgeons. Beside, in the last fifteen years adipose
tissue has been reappraised also for a different reason. In fact, nearly forty years after the
identification of bone marrow stem cells, it has been gathering attention for the opportunity
to obtain autologous pluripotent adipose-derived stromal stem cells (ADSCs). This population
of cells has been extensively investigated and it currently holds out many hopes for prospective
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stem cell therapies for the repair and regeneration of various tissues and organs in a large
number of different diseases. Thus, over the past years, this field has become a very active and
attractive area of clinical and experimental research, providing significant outcomes and
reaching important milestones. Today adipose tissue embodies an hot spot of regenerative
medicine that may give rise to a new era of active stem cell therapy.
2. Purpose
2.1. Meeting the adipose tissue
Giving the increasing amount of experimental and clinical data regarding adipose tissue and
ADSCs, in this chapter we are going to briefly review the concepts and the insights behind the
role of adipose tissue in regenerative medicine and tissue engineering. In particular we are
going to focus the attention on current cutting edge translational research from bench to
bedside, including the investigation of biological properties of ADSCs, the state of art of their
manipulation, the latest progresses in their clinical adoption, the development of bio-engi‐
neered products and the actual therapeutic prospective opportunities.
3. Basic science background
3.1. The outline and the anatomy of adipose tissue
Adipose tissue is a complex and multi-depot organ, constituted for one third by mature
adipocytes and for the other two thirds by a combination of a large variety of other cells. [1]
Among represented cell lines are included small blood vessels, nervous cells, fibroblasts and,
importantly, adipocyte progenitor cells, also known as preadipocytes or Adipose Derived Stem
Cells (ADSCs). Evolution has preserved in mammals two histologically different qualities of
adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT), which are composed
by different types of mature adipocytes [Table 1]. In particular, white adipocytes are spherical,
having a diameter ranging between 30 and 70 μm according to the amount of lipid depots, and
lipids within the cells are organized in a single large "uni-locular" droplet, the size of which can
exceed 50 μm. Thus, the lipid droplet occupies the vast majority of the whole intracellular space,
pushing the remaining cytoplasm and nucleus into a thin marginal rim. On the other hand, brown
adipocytes are polygonal with a centrally placed nucleus and their cellular size ranges from 20
to 40 μm. They accumulate lipids in smaller "multi-locular" droplets and they are rich of specific
mitochondria, containing the protein UCP-1 which is responsible for uncoupling of oxidative
phosporylation and production of heat. WAT and BAT are both innervated by noradrenergic
fibers of the sympathetic nervous system. As for the vascularization of adipose tissue, white
adipocytes are organized in collections of fat lobules, each supplied by a selective arteriole and
surrounded by septae of connective tissue. An individual adipocyte is supplied by an adjacent
capillary and it is associated to a glycoprotein layer, reticular fibrils, fibroblasts, mastocytes and
macrophages. Compared to WAT, BAT provides a more extensive vascular tree, characterized
by dense multiple capillaries. The relevant vascularization of the latter in combination with the
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presence of a significantly high number of mitochondria, account for the typical "brown" color.
WAT and BAT have also different roles in energy metabolism. Primary function of white
adipocytes is to store excess energy as lipid, which is then mobilized in response to metabolic
needs. Brown adipocytes, on the other hand, use accumulated lipids primarily as a source of
energy released in the form of heat. WAT can be found in several anatomically distinct and
separate collections, or "depots." There are two major anatomic subdivisions of these depots,
each showing unique anatomic, metabolic, endocrine, paracrine, and autocrine properties: intra-
abdominal or visceral adipose tissue and subcutaneous adipose tissue. In addition, WAT can
also be found in small amounts of fatty layers surrounding other organs, such as the heart, kidney
and  genitalia.  Intra-peritoneal  fat,  composed  of  omental  and  mesenteric  adipose  tissue,
comprises the vast majority of visceral fat. Importantly, subcutaneous adipose tissue shows
different structural features in different anatomical districts.  [2] In fact,  fat depots in the
abdominal area are characterized by the presence of large adipocytes, densely packed togeth‐
er and surrounded by a poor stromal (collagen) network. Instead, in more localized depots (such
as throcanteric areas, the sovra-pubic area, arm pits, medial regions of the knees, tights, arms,
pectoral and mammary areas) adipocytes present a smaller diameter, a more represented stromal
component and a more extensive vascular network. BAT in newborns and children can be found
in several body areas. However, while in other small mammals these depots persist during
growth, in humans brown adipocytes undergo a morphologic transformation, rapidly accumu‐
lating lipids,  becoming uni-locular and losing their  typical  ultrastructural  and molecular
properties, including mitochondria [Figure 1.]. As a consequence, there are no discrete collec‐
tions of BAT that can be found in human adults.
White Adipocyte Brown Adipocyte
Shape Spherical Polygonal
Diameter 30-70 µm 20-40 µm
Ultra-structure One large “unilocular”
lipid droplet, cytoplasm
and nucleus compressed
into a thin visible rim
Multiple smaller “multilocular” droplets, high content of
mitochondria, centrally placed nucleus
Innervation Noradrenergic fibers,
confined to capillary wall
Noradrenergic fibers, directly interfacing plasma membrane
Vascularization Supplied by an adjacent
capillary
Richer vascular tree, dense with multiple capillaries









Several areas in newborn, no discrete collections in adult.
Probably isolated cells scattered between WAT depots
Table 1. Main differences between White and Brown adipocytes.
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Figure 1. Monolayered culture of adipocytes in vitro with adipogenic medium.
3.2. The living image of adipose derived stem cells
The understanding of biochemical characteristics, molecular/cellular biology, immune-
biological characteristics and phenotype of adipose tissue has significantly advanced in the
last years. Adipose tissue has shown to consist mostly of cells of mesenchymal origin with few
others endothelial cells, smooth muscle cells and pericytes, all showing low levels of cell
senescence. Adipose tissue derives from the mesodermal layer of the embryo and develops
both during pre-natal and post-natal growth. The microscopic location of the adipogenic
progenitor cells in the adult is still controversial. [3] It remains to be proven whether the origin
of the cells correlates with endothelial, pericytic or stromal compartments. A large number of
surface antigens are in common with endothelial cells, suggesting a common origin. According
to some researchers, adipogenic progenitor cells could be released directly by the bone marrow
and distributed systemically by blood flow: experimental evidences of bone marrow derived-
cells capable of differentiating into adipocytes in vivo have already been described but the
contribution of these circulating cells to the overall growth and development of adipose tissue
is still under investigation. Mesenchymal stem cells (MSC) were first described as immature
cells in the bone marrow, capable to give rise to mesenchymal lineages such as osteoblasts,
chondrocytes and adipocytes. [4] MSCs represent a small fraction of nucleated cells of human
bone marrow (0.01%-0,0001%). MSCs are defined by three minimal criteria, as established by
the International Society for Cellular Therapy in 2005: adherence to plastic dishes, specific
surface antigen (CD73+, CD90+, CD105+, CD45-, CD34-, CD14 or CD11b-, CD79- or CD19-,
HLA-DR) and in vitro capability to give rise to adipocytes, osteoblasts and chondrocytes. A
similar protocol has been used for a long time to isolate adipose tissue progenitors: the resulting
immature adherent cells were thus called pre-adipocytes. To obtain these cells fat pads are
minced and digested with collagenase, separating an upper layer of floating mature adipocytes
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from a lower layer of pelleted stromal vascular fraction (SVF). [5] The SVF is an heterogeneous
cell population of circulating blood cells, fibroblasts, pericytes, endothelial cells and pre-
adipocytes. Pre-adipocytes may be isolated from the SVF by plating and washing. This cell
population, adopting appropriate differentiating agents, can give rise to mature adipocytes,
demonstrating their nature of adipose progenitors. Cell cultures have provided evidence of
regenerative capacities in both the heterogeneous stromal vascular fraction (SVF) and in the
more homogeneous adipose-derived stem cells (ADSCs). In 2002 pre-adipocytes were better
characterized and they were demonstrated to show clear multi-potency potential: thus, they
were named Adipose Derived Stem Cells (ADSCs). [6] In particular, ADSCs represent a
mesodermal stem cell population with clonal mesodermal, ectodermal, and endodermal
potentials capabilities that express multiple CD marker antigens similar to those of other
mesenchymal stem cells as those residing in bone marrow. Several investigations have
reported a differentiation into adipogenic, osteogenic, chondrogenic and myogenic lineages
in vitro by means of specific culture media. In particular, the potential to differentiate into non-
mesodermal lineages is exciting. The differentiation into neural precursors, which are of an
ectodermal origin, has been described. In addition, evidence of differentiation into hepato‐
cytes, pancreatic islet cells, endothelial cells and other epithelial cells has been provided in
different reports. By definition, a stem cell is characterized by the ability to self-renew and to
differentiate along multiple lineage pathways. Since the self-renewal of ADSCs has not been
fully established yet, it is accepted that some investigators may use the same acronym to mean
"adipose-derived stromal cells", in agreement with the statement of the International Society
for Cellular Therapy. Indeed, ADSCs present several differences from MSCs at genomic,
proteomic and functional levels. For instance, during the earliest rounds of proliferation,
ADSCs express the CD34 antigen: the frequency of these cells is much higher (100 to 500 folds
higher) than that of MSCs in the bone marrow. In addition, MSCs are probably more committed
towards osteoblastic and chondrogenic lineages than ADSCs. Thus, although numerous
author use the same term “MSCs” both for cells derived from bone marrow and for those
derived from adipose tissue, MSCs and ADSCs are probably two distinct cell populations. A
more precise definition of ADSCs, based on their immune-phenotype and/or differentiation
capabilities, has not been yet provided. Some authors believe that ADSCs are a heterogeneous
group of progenitor cells with differences in their stem cell potential. Thus, ADSCs and SVFs
cells represent an autologous alternative to pluri-potent embryonic stem cells with a multi-
lineage differentiation potential, a significant therapeutic impact and a critical role in the
rapidly expanding fields of tissue engineering and regenerative medicine. Significantly,
further investigations are needed to better clarify these aspects. Importantly, the most
important characteristics of ADSCs, with a possible interest for clinical applications, comprise
their multi-potency, secretory functions and immune-modulatory capabilities.
3.2.1. Differentiation potential of ADSCs
ADSCs, like MSCs, have the ability to differentiate into mesodermal cells, such as adipocytes,
fibroblasts, myocytes, osteocytes and chondrocytes, in a process called lineage-specific
differentiation. The increasing evidence for the ability of ADSCs to differentiate into cells of
non-mesodermal origin such as neurons, endocrine pancreatic cells, hepatocytes, endothelial
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cells and cardiac myocytes, is surprising. This process is called “cross-differentiation”.
Lineage-specific differentiation can be tracked at a molecular level by the expression of key
transcription factors of mature tissues. The earlier stages of differentiation, named "allocation"
or "commitment", that drive the ADSCs into the specialized lineage are not completely known
yet. In vitro, the differentiation of multi-potent cells into a desirable cell phenotype can be
obtained by appropriate culture conditions and stimulation with a cocktail of known differ‐
entiating agents [Table 2].
Type of differentiation Stimulating factors
Adipogenic Insulin; isobutylmethylxanthine (IBMX) ; dexamethasone; rosiglitazone;
indomethacin.
Osteogenic Dexamethasone; β-glycerophosphate; vitamin D3; bone morphogenetic
protein (BMP-2)
Chondrogenic insulin growth factor (IGF); BMPs; transforming growth factor-β (TGF-β)
Myogenic/cardiomyogenic Dexamethasone; hydrocortisone; IL-3; IL-6
Vascular/endothelial Specific environment
Neurogenic Valproic acid; epidermal growth factor (EGF); fibroblast growth factor
(FGF); nerve growth factor (NGF) and brain-derived neurotrophic factor
(BDNF)
Tendinous FGF; platelet derived growth factor (PDGF-BB); EGF; TGF-β; IGF-1; BMPs
Table 2. Experimental growth factors used for differentiation of ADSCs in different cell lineages.
• Adipogenic differentiation
ADSCs have an exceptional potential for differentiation into mature adipocytes, which is very
promising in developing techniques for repairing soft-tissue defects. [7] Differentiation can be
induced by a large variety of substances, including insulin, dexamethasone, rosiglitazone and
indomethacin. During differentiation ADSCs, initially showing a fibroblast-like spindle or
stellate shape, undergo morphologic changes with the appearance of one or more lipid
vacuoles and they begin to express several genes and proteins characterizing the mature
adipocyte, including leptin, peroxisome-proliferating activated receptor γ (PPARγ), glucose
transporter type 4 (GLUT4) and glycerol-3-phosphate dehydrogenase (GPDH).
• Osteogenic differentiation
Osteogenic differentiation can be induced in vitro by supplementing the culture medium with
dexamethasone, β-glycerophosphate and vitamin D3. The acquisition of the osteoblast
phenotype is accompanied by expression of specific genes and proteins, including alkaline
phosphatase, type I collagen, osteopontin, osteonectin, and Runx2. Osteogenic differentiation
may also be obtained by transfection of osteogenic lineage-determining genes (BMP2 and
Runx2): this approach has proved to be effective both in vitro and in vivo in a large number
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of reports. These experimental findings hold great promise for the use of ADSCs in bone
regeneration.
• Chondrogenic differentiation
Insulin growth factor (IGF), bone morphogenetic proteins (BMPs), and transforming growth
factor-β (TGF-β) have shown to induce chondrogenic differentiation of ADSCs when added
to the culture medium. Chondrogenic differentiation occurs also by seeding ADSCs into poly-
glycolic acid (PGA) scaffolds, as it was largely demonstrated in several other in vitro models
and in vivo in nude mice.
• Differentiation into other lineages
Terminally differentiated myoblasts can be obtained in vitro, showing the ability to form
multinucleated myotubules and to shrink/diastole under the influence of atropine. This
property of ADSCs is of particular interest for the treatment of genetic muscular dystrophies:
preclinical in vivo studies on animal models are currently ongoing. In addition, other studies
have focused on the capability of ADSCs to differentiate into cardiomyocytes with a possible
application in heart regeneration or repair after an ischemic injury. Furthermore, endothelial
regeneration is another important field of research: ADSCs have shown to be able to differen‐
tiate into endothelial cells and to secrete several pro-angiogenic factors, like vascular endo‐
thelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Differentiation into
neuron-like cells has also been reported by different authors: ADSCs may acquire a neural-
like morphology and they may express several proteins specific for the neuronal phenotype
(Neuron Specific Enolase; Neuron Specific Nuclear Protein). Finally, some studies have
explored the chance for ADSCs to differentiate into pancreatic islet cells, hepatocytes and
epithelial cells with the purpose to find an alternative cellular therapy for diseases such as
diabetes mellitus and liver disfunction: data and outcomes are however still preliminary and
lacking of strong evidence.
3.2.2. ADSCs as a secretome
Importance of ADSCs does not only reside in their potential to differentiate in mature lineages.
Similarly to the original adipose tissue from which they can be isolated, ADSCs have shown
to act as a “secretome”, accurately regulating proteins and growth factors secreted into the
extracellular milieu and having a relevant impact on different organs and systems within the
human body [Table 3.]. [8] Trophic effects of ADSCs include stimulation of angiogenesis,
hematopoietic support, gene transfer and suppression of inflammation. Indeed ADSCs
represent a source of several cytokine/soluble factors regulating the survival and differentia‐
tion of various endogenous cells/tissues. A large number of these molecules have been related
to the regenerative attitude of ADSCs: among these, we may include hepatocyte growth factor
(HGF), granulocyte and macrophage colony stimulating factors, interleukins (ILs) 6, 7, 8 and
11, tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor (VEGF), brain
derived neurotrophic factor (BDNF), nerve growth factor (NGF), adipokines and others. Full
characterization of the secretory profile of ADSCs, either by immune-enzymatic techniques
(ELISA) or by mass spectrometry, is still object of investigation. Several adipokines such as
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adiponectin, angiotensin, cathepsin D, penetraxin, pregnancy zone protein and retinol binding
protein, as well as stromal cell-derived growth factor (CXCL12) have been found in the
conditioned media of ADSCs differentiating towards the adipocyte lineage. ADSCs secrete
also oher different well characterized cytokines (GM-CSF, TGF-β, PGE2, IGF-1) and their
release can be modulated by exposure to different agents, such as b-FGF and EGF or inflam‐
matory stimula, like lipopolysaccharide (LPS). The role of these and other factors has been
investigated by multiple studies regarding one or more possible applications of ADSCs in the
field of regenerative medicine. Brain Derived Neurotrophic Factor (BDNF), Nerve Growth
Factor (NGF), Glial Derived Neurotrophic Factor (GDNF) are thought to be important
molecules secreted by ADSCs mediating neurotrophic effects and modulating in animal
models of Parkinson Disease the recovery after hypoxic-ischemic injuries. Hepatocyte Growth
Factor (HGF) and Vascular Endothelial Growth factor (VEGF) are the most important factors
capable of inducing angiogenesis in areas that have undergone ischemic episodes and their
importance is particularly relevant in wound healing. In cardiac regeneration, IGF-1 and VEGF
mediate respectively an anti-apoptotic and angiogenic action, to which is attributed the
capacity of ADSCs to have beneficial effects when transplanted/injected in different animal
models of myocardial infarction/failure. In conclusion, most of ADSCs secreted factors act
through mechanisms that mediate protection against cell death or, alternatively, induce cell
migration and proliferation. Alternatively, they can indirectly act on the targeted cell popula‐
tions: by promoting vascularization they can be indirectly linked to an increase of oxygen and
nutrients in the affected areas, which may in turn promote local regenerative processes. Indeed,
up to now most reports have focused on a limited set of known factors but it is expected that
other molecules are responsible for the regenerative effects of ADSCs.
3.2.3. Immunomodulatory properties of ADSCs
The regenerative potential of ADSCs has been related also to their immune-modulatory
abilities. ADSCs have been shown to be an immune-privileged site, preventing severe graft-
versus-host response after transplantation procedures in vitro and in vivo. A concern of
fundamental importance is the interplay between ADSCs and the host tissue, with particular
focus on the immune system. Several studies have shown that ADSCs can be used either for
autologous or allogenic cell transplants: this feature would be a major advantage for the
employment of adipose tissue as a source for cell-based therapies. Furthermore ADSCs seem
to act also as modulators of the immune system. The allogenic potential of these cells could be
explained by the property of ADSCs to decrease the expression of hematopoietic markers and
HLA-DR after subsequent passages. In addition, it has been observed that ADSCs only express
HLA class I, but not HLA class II molecules: the latter can only be induced in ADSCs after
incubation with IFN-γ. Furthermore, several experiments have proved that ADSCs do not
stimulate lymphocyte proliferation and they do not elicit a response by Mixed Lymphocyte
Reaction (MLR): in addition, they can also inhibit phyohemagglutinin (PHA)-stimulated
lymphocyte proliferation. These immune-suppressive effects are likely mediated by soluble
factors, among which PGE-2 seems to be the most important. Notably, the secretion of
cytokines by ADSCs can be modulated not only by the inflammatory stimulus but also by the
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surface upon which they are seeded: thus the bio-scaffold/environment provided could be
another mechanism to control the immune-modulatory properties of ADSCs.
Main properties of ADSCs
Differentiation potential Into cells of mesodermal origin: adipocytes, fibroblasts, myocytes, osteocytes,
condrocyes
Into cells of non-mesodermal origin: endothelial cells, neuronal-like cells, pancreatic
islet cells, hepatocytes
Secretion of soluble factors
(ADSCs “secretome”)
Adiponectin, angiotensin, cathepsin D, penetraxin, pregnancy zone protein, retinol
binding protein, CXCL12, HGF, GM-CSF, ILs 6 ,7, 8, 11, TNF-α, VEGF, BDNF, NGF,
GDNF, IGF-1, TGF-β, FGF-2, PGE2,
Immunomodulatory capabilities Allogenic cell transplant potential
Lack of response by MLR,
Inhibition of PHA-stimulated lymphocyte proliferation
Table 3. Synopsis of properties of ADSCs.
4. Manipulation of adipose tissue and ADSCs
4.1. Introduction
Human subcutaneous adipose tissue provides an ideal alternative source of autologous
pluripotent stem cells showing several advantages compared with other sources. As a matter
of fact it is ubiquitous and commonly easily obtainable in large quantity with minimal invasive
harvesting procedures or methods (either liposuction aspirates or subcutaneous adipose tissue
fragments), limited patient discomfort and minimal ethical considerations: it may be trans‐
planted safely and efficaciously. The abundance of stem cells available enables the direct
therapeutic adoption of primary cells without any need for culture expansion. Moreover,
adipose tissue is also uniquely expandable: currently available procedures for cell isolation
yield a high amount of stem cells with remarkable properties of stable proliferation and
potential differentiation in vitro, being attractive candidates for clinical applications offering
protocols that may provide alternative therapeutic solutions in cell-based therapies and tissue
engineering to repair or regenerate damaged tissues and organs. The technologies for adipose
tissue harvesting, processing, and transplantation have substantially evolved in recent years
together with appropriate commercial development and with updated refinements and
information regarding extraction, isolation, storage, options for cultures, growth and differ‐
entiation, cryopreservation and its effect on survival and proliferation of isolated ADSCs, also
related to their adoption in tissue-engineered constructs involving biomaterials and scaffolds.
Inconsistencies in literature regarding the handling of ADSCs require more extensive inves‐
tigations and controls, in particular in the in vitro processing and differences between the
regenerative properties of freshly-processed heterogeneous stromal vascular fraction cells and
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of culture-expanded relatively homogeneous ADSCs, or the related risk of complications and
possible adverse events. There is a need for stronger evidence of the safety, reproducibility
and quality of the ADSCs prior to a more extensive use in clinical applications. As a matter of
fact, despite the clinical use of adipose tissue grafts and ADSCs worldwide has dramatically
increased, questions concerning the safety and efficacy of these treatments are still opened and
currently the use of isolated ADSCs for medical indications in a clinical setting has been
approved only in selected cases and few countries.
4.2. Origins and delivery of adipose tissue grafts
Adipose  tissue  have  been  used  for  long  time  for  reconstructive  purposes  through  fat
grafting or autologous fat  transfer,  a  method according to which fat  from the patient is
removed from one area of the body ad reinserted into the desired recipient location. [9]
Fat  grafting  has  shown to  be  beneficial  as  a  reconstructive  and cosmetic  procedure  for
patients with volume losses to soft  tissues due to disease,  trauma, congenital  defects  or
aging.  Even so,  outcomes of  these techniques are  often unpredictable  and rates  of  graft
reabsorption may be disappointing. As a matter of fact, fat tissue is re-vascularized at the
transplantation site within 48 hours from the surgical procedure, in the meantime being
fed by diffused materials from surrounding free plasma. The survival rates of the graft are
dependent on size of transplanted fat particles and on surface area from which these cells
could  re-establish  their  blood  supply.  In  order  to  minimize  reabsorption,  studies  have
demonstrated the efficacy of less traumatic methods of harvesting, processing and injecting.
Microinjection of fat by means of the "lipostructure technique" known also as Coleman’s
technique has been adopted by many plastic surgeons. [10] This technique distributes fat
grafts in small aliquots by meticulous injection through multiple access sites, from which
the graft fans out into various subcutaneous layers. The abundance of stem cells obtaina‐
ble in many common procedures, such as liposuction and liposculture, enables their direct
therapeutic adoption without any need for culture expansion. [11] Even so, precursor cells
can be purified by a  variety of  processes  and enzymatic  techniques may be adopted to
obtain an ADSC-rich stromal vascular fraction (SVF). This issues are currently investigat‐
ed  as  adjuvants  to  free  fat  transfer  in  order  to  increase  yield  of  graft  retention  (cell-
assisted  lipotransfer).  The  ADSCs  contained  in  the  stromal  vascular  fraction  have  been
applied  clinically  as  early  as  2004  for  the  treatment  of  perianal  fistulas  in  Crohn's  dis‐
ease.  [12]  However,  it  is  worth  pointing  out  that,  even  though  harvesting  and  first
processing steps overlap, fat grafts SVF cells and ADSCs represent three different therapeu‐
tic  options.  Fat  grafts  are  obtained  directly  after  centrifugation  of  lipoaspirates.  They
contain predominantly mature adipocytes and are poor in ADSCs. The stromal vascular
fraction,  as  mentioned above,  is  obtained by digestion with collagenase of  the  lipoaspi‐
rate sample and a subsequent centrifugation step: its cellular composition is heterogene‐
ous, being rich in ADSCs but containing also circulating blood cells, fibroblasts, pericytes
and endothelial cells. The adoption of a pure ADSC population requires plating of the SVF
and expansion of  the  stem cell  population  and thus,  differently  from the  previous  two
options,  ADSCs cannot be harvested and implanted in a one step-procedure.  Even if  all
these approaches exploit to some extent the regenerative potential of adipose tissue they
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are  quite  different  procedures  having also different  therapeutic  indications.  Thus,  atten‐
tion has to be paid in order to avoid confusion. As for harvesting of ADSCs, several factors
related to the patient,  such as Body Mass Index (BMI) and age,  have been analyzed for
their impact on cell viability and number. Results are controversial,  there is no evidence
of a strong correlation of BMI with stem cells viability, number or size. Instead, there seems
to  be  a  negative  correlation  between  age  and  rates  of  pre-adipocytes  proliferation  or
differentiation, with higher lipolitic activity in the younger population and lower levels of
apoptosis.  [13]  The body region of  the donor site  is  another important  variable  patient-
dependent.  The abdomen,  according to  some studies,  seems to  be  the  best  harvest  site,
while medial  thigh and knee seem to have the lowest levels of  viability of  ASDCs. [14]
These  differences  have  not  been  proved  in  other  studies.  Effects  of  infiltration  of  local
anesthetics during harvesting have also been investigated: lidocaine and adrenaline seem
to have no effects on adipocyte viability. The method of harvest can affect not only viability
of  ADSCs but  also their  level  of  adhesiveness to  extracellular  matrix  proteins.  Standard
liposuction allows the harvest of larger volumes of adipose tissue but it might result in up
to 90% rate of adipocyte rupture. For this reason this technique is not ideal for fat grafting,
while it could be more appropriate for ADSCs harvesting. An equivalent damage to pre-
adipocytes has been measured comparing syringe aspiration with fat surgical excision. It
is accepted that a larger cannula diameter at harvest correlates with improved cell viability.
Partial purification of lipoaspirate can be carried out in the operatory room. The first step
is centrifugation, which separates harvested fat into three layers: infra-natant (lowest layer
composed of blood, tissue fluid and local anesthetics), middle portion (mostly composed
by fatty  tissue)  and supra-natant  (least  dense upper layer  including lipids).  Infra-natant
components can be ejected from the base of the syringe, while supra-natant can be poured
off  and soaked up using absorbent materials.  While  this  technique is  the most  practical
and today commonly used for fat grafting, it may not produce the best fraction of ADSCs
possible. Several studies have been conducted on this issue, revealing that gentle centrifu‐
gation  produces  the  highest  cell  viability,  while  long  periods  of  centrifugation  lead  to
isolation of  the  most  proliferative  cell  type.  When comparing decantation,  washing and
centrifugation, stem cells concentration results greater in washed lipoaspirates and pellets
contained at  the bottom of the centrifuged samples contain the highest  concentration of
stem cells.
4.3. Origins and delivery of ADSCs
Embryonic stem cells have an enormous multilineage potential but many ethical and political
issues accompany their use. Therefore researchers have directed their attention on pluripotent
adult stem cells. Adult stem cells were initially thought to have the differentiation capacity
limited to their tissue of origin, however, as already mentioned above, many studies have now
demonstrated that stem cells have the capacity to differentiate into cells of mesodermal,
endodermal and ectodermal origin. MSCs from the bone marrow show extensive proliferative
capacity and a multilineage differentiation potential into several lineages, including osteo‐
blasts, chondrocytes, adipocytes and myoblasts. However, pain, morbidity and low cell
numbers upon harvest represent an obstacle to their extensive clinical application. The
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harvesting of adipose tissue, in comparison, is much less expensive than bone marrow. ADSCs
can be isolated both from tissue samples and from lipoaspirate with less invasive procedures
and are available in greater quantities (5 x 105 stem cells from 400 to 600 mg tissue). [15] ADSCs
can be easily cultured and expanded, retaining their stem cell phenotypes and mesenchymal
pluripotency still after several passages, features that make them an ideal source of stem cells
for clinical applications.
• Isolation and culture of ADSCs
Since Rodbell’s description of isolated pre-adipocytes from adipose tissue, a variety of methods
have been developed. [16] Today, most laboratories use several common steps to process cells
from adipose tissue. These methods include: washing, enzymatic digestion/mechanical
disruption, centrifugal separation for isolation of cells which can be used directly, after
cryopreservation, or after culture expansion for the generation of ADSCs. Still, despite the
extensive use of ADSCs for research purposes, there is no any widely-accepted unique
standard protocol for isolating and culturing these cells. For enzymatic digestion most
laboratories use collagenases of different subtypes, trypsin, or a mixture of both, at various
concentrations with an average incubation time of one hour, at 37°C, in constant shaking. The
optimal centrifugation speed is considered to be around 1200g for 5 to 10 minutes. Some
additional purification procedures can include filtration through nylon meshes and incubation
with an erytrocyte-lysing buffer, usually Krebs Ringer Buffer (KRB) or NH4Cl. This procedure,
however, seems to have a negative influence on the growth of ADSCs. Some investigators,
after the identification of ADSCs surface immunophenotype, use immune-magnetic beads or
flow cytometry to purify the stem cell population directly from the heterogeneous sample,
using the CD34+ antigen. The most used culture medium are α-Modified Eagle's Medium (α-
MEM), or Dulbecco's Modified Eagle's Medium (DMEM), after addition of fetal bovine/calf
serum, (FBS/FCS), L-glutamine, penicillin and streptomycin.
• Cryopreservation of ADSCs
The development of simple but effective storage protocols for adult stem cells will greatly
enhance their use and utility in tissue-engineering applications. [17] Cryopreservation is
regarded as a promising technique and many studies have focused on this procedure. Other
protocols investigated drying (anhydrobiosis) and freeze drying (lyophilization). The majority
of in vitro studies agree that cryopreservation of adipocytes in liquid nitrogen, preferably using
a set cooling and re-warming protocol, provides the lowest damage to cell viability. These
results have been replicated in vivo (murine models) showing that grafts frozen in liquid
nitrogen and stored at -35°C had a similar viability and histology compared to fresh tissue: in
addition, this method obtained better results than freeze drying and immersion in glycerol.
Recently, in order to increase the yield of adipose-derived stem cells post-thawing, the use of
cryoprotective agents, such as dimethyl sulphoxide (DMSO) has been examined: samples
frozen with DMSO achieved better outcomes than unprotected ones. Thus, cryoprotective
agents are now considered as an essential part of any cryopreservation protocol aiming to
provide appropriate conditions for the survival of ADSCs and adipocytes.
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4.4. Safety concerns
Inconsistencies in literature regarding the handling of ADSCs require more extensive inves‐
tigations and controls. In particular, a focus should be placed on in vitro processing as well as
differences between the regenerative properties of freshly-processed heterogeneous adipose
cells and those of culture-expanded relatively homogeneous ADSCs. Related risks of compli‐
cations and possible adverse events like fat necrosis, seromas, oncological recurrences, should
be accurately considered. In addition, adiponectin is implicated in the pathogenesis of insulin-
resistant states, such as obesity and diabetes type 2. In particular, several studies reported that
differentiated WAT cells and WAT resident progenitors may promote cancer growth and
metastasis by means of a variety of different mechanisms (endocrine, paracrine, autocrine
interactions). The main cellular component of WAT are adipocytes, the large cells accumulat‐
ing tryglicerides in lipid droplets. In particular, in conditions like obesity, adipocytes in WAT
may eventually became under oxygenated, leading to hypoxia, increased oxidative stress,
recruitment of inflammatory leukocytes and eventually fibrosis. In recent experimental
models, some adipokines showed to be able to promote tumor growth along with fatty acids
released by adipocytes. High levels of adiponectin have been associated with the development
of endometrial carcinoma and breast cancer. Leptin has been identified in regulation of cell
proliferation and neo-vascularization in malignant and normal cells of different origins,
including lung, gastric, colonic, kidney, leukemic, hematopoietic and epithelial cells. Notably,
these molecules can enhance proliferation and survival of malignant cells and/or of tumor
vasculature. So far, studies investigating the role of WAT in cancer have predominantly
focused on pro-tumorigenic effect of ADSCs. In fact the increased proliferation and survivor
of malignant cells may result from the engagement of perivascular ADSCs into angiogenesis
and vascular maturation, resulting in improved tumor blood perfusion. Cytokines such as
adiponectin, leptin, interleukin-6, and TNF alfa seem to be responsible for a chronic low-grade
inflammation. Furthermore, mesenchymal cells are known to suppress the activation of T-
killer cells: this finding suggests that also ADSCs may help tumors to evade the host immune
response. Thus, adipocytes may be able to produce adipokines and several secretions which
could potentially induce cancer reappearance by “fueling” dormant breast cancer cells in
tumor bed true “tumor-stroma interaction”: even so, up to now, especially for grafting of
adipose tissue after breast cancer treatment, there is no strong clinical evidence or international
agreement on this topic. [18-19] Depending on country, the safety of adipose tissue grafting is
still a controversial issue. In 2009, the American Society of Plastic surgeons Fat Graft task Force
concluded that no reliable studies could confirm definitely the oncologic safety of lipofilling
in breast cancer patients. A more accurate point of view is provided by a large multicentric
observational study on adipose tissue grafting in patients previously affected by breast cancer:
considered parameters included the complication rate of the technique, the risk of modification
of mammography and a rigorous long-term clinical/instrumental follow-up. [20] At the
moment no studies on the effects of lipotransfer on human cancer breast cells in vivo are
available. We cannot provide the definitive proof of the safety of lipofilling in terms of cancer
recurrence or distant metastasis, but until then, should be performed in experienced hands,
and a cautious oncologic follow-up protocol is advised.




5.1. The regenerative cells
The growing interest in this area of research has driven the adoption of adipose tissue and
ADSCs in a wide number of clinical situations, medical fields and conditions for the repair and
regeneration of acute and chronically damaged tissues, with an increasing number of trans‐
lational efforts. Clinical trials have been advanced in order to investigate the therapeutic
potential and applicability of these cells based on the induction of their properties similar to
that observed in BMSCs. An extensive great knowledge concerning the harvesting, character‐
ization and transplantation of ADSCs has been developed. Even so, current literature still lacks
of strong evidence about the clinical potential of ADSCs and adipose tissue. In particular this
may be due to the fact that human lipoaspirates may significantly differ in purity and molec‐
ular phenotype and that many reports have adopted heterogeneous populations of cells
providing uncertain results. Remarkably, some problems still affect the correct interpretation
of outcomes. One of the most significant issues limiting the interpretation of clinical progres‐
sion is the lack of standardization in defining ADSCs, since both SVF and ADSCs may be used.
[4] Another issue is whether ADSCs operate on tissue regeneration through direct trans-
differentiation or paracrine mechanisms based on the secretion of numerous cytokines and
growth factors. Thus, standardization of a method and improvement of current preclinical
data may allow direct comparison of different results as well as a better definition of clinical
potential of ADSCs. Current preclinical and clinical data of such cell-based therapies should
include the osteogenic, chondrogenic, adipogenic, muscular, epithelial and neurogenic
differentiation of progenitor, endothelial, and mesenchymal stem cells involved. Thus, skin,
bone, cartilage, muscle, liver, kidney, cardiac, neural tissue, pancreas represent some of the
most prominent clinical targets on which these therapies are focused. ADSCs are commonly
adopted in clinical settings in surgical fields such as: cell-enriched lipotransfers, soft tissue
augmentations and reconstructions of defects after trauma or oncologic surgery, healing of
chronic wounds (phase 1 trials for the healing of recurrent Crohn's fistulae), skin regeneration
and rejuvenation (repair of damages induced by aging or radiations), scar remodeling. In
addition, they have been adopted in the treatment of cardiovascular disease, metabolic disease
and encephalopathy (cerebral infarction) and a wide range of other surgical needs by ortho‐
pedic surgeons, oral and maxillofacial surgeons and cardiac surgeons. Indeed, the clinical
application of adipose tissue relies on convincing results but the full therapeutic potential of
ADSCs may still need further investigation.
5.1.1. The “Lipofilling technique”
Fat graft has been initially adopted to generate adipose tissue in the treatment of contour
deformity or volumetric defects. The “lipofilling technique” has been used for many years and
it has become rapidly popular especially in aesthetic surgery to improve cosmetic results in
facial surgery. In fact it may be considered an ideal filler since it is totally biocompatible, readily
available, inexpensive and it enables good aesthetic results. More variable are the application
of fat injection in reconstructive surgical treatments. For example in breast reconstruction the
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indication of lipofilling include micromastia, tuberous breasts, Poland syndrome, post-
lumpectomy deformity, post-mastectomy deformity, sequelae of post-radiotherapy (every
anatomical region previously subjected to radiotherapy is subject to fat injection), refinement
of secondary reconstructions after flap or prosthesis reconstruction and nipple reconstruction.
In head and neck reconstructive surgeries it has been used to correct Treacher Collins syn‐
drome o other cranio-synostosis. In burns, lipofilling has been adopted to improve the
structural features of extracellular matrix in the treatment of burn sequaele, such as pathologic
scars, with the aim to restore a more physiologic skin architecture. The lipofilling is also a
valuable option to enhance volumes in facial hypotrophies, for example in patients affected
by HIV-related lipo-distrophy. In addition, fat injection has proved to be very useful to
improve local vascularization and trophism in chronic ulcers, especially vascular or post-
traumatic ulcers.
Figure 2. Injection of autologous adipose tissue (“lipofilling technique”) in a scar.
5.1.2. Clinical trials with ADSCs
Most of clinical trials on humans are based on previous experiments on animal models. The
evidence of the ability of ADSCs to differentiate into cells of non-mesodermal origin has been
tested in some models in treatment of several diseases. The ADSC-derived hepatocytes
transplanted into nude mice restored liver function and freshly isolated ADSCs could differ‐
entiated into hepatocytes after intrasplenic transplantation into nude mice in vivo, supporting
their application in clinical setting. [21] However clinical trials are still mostly lacking of
Adipose Derived Stem Cells: Current State of the Art and Prospective Role in Regenerative Medicine...
http://dx.doi.org/10.5772/55924
193
promising results. [4] A recent study showed that the direct injection of ADSCs could restore
blood flow in a mouse ischemic hindlimb model, as confirmed by clinical data. [22] The
myogenic differentiation of ADSCs may be used in the treatment of muscular diseases such
as Duchenne dystrophy and for regenerative cell therapy in heart failure. [23] Other novel
potential clinical uses of ADSCs include the treatment of Alzheimer disease, of multiple
sclerosis due to the anti-inflammatory effect of ADSCs, of neurogenic bladder and other
neurologic disorders. A preliminary study showed that peri-urethral injection of autologous
ADSCs acts positively in stress urinary after prostatectomy. Regarding current clinical
applications of ADSCs, apart from a phase III trial on the treatment of Crohn’s fistula, most
clinical trials are in phase I. Beside the use in breast reconstruction, trials are in progress to
treat acute myocardial infarction and chronic myocardial ischemia by intracoronary injection
of SVF. Other trials are focused on the treatment of cirrhosis and of diabetes I or II. [4] Another
trial adopted ADSCs (after purification and expansion) for the management of fistulas
associated or not to Crohn’s disease: results demonstrated an efficient control of inflammation
and an improvement of healing process, most likely due to paracrine action that cells differ‐
entiation. Another trial investigated the restoration of volumes in hypotrophic scars after
subcutaneous injection of ADSCs. Only two trials have studied the effect of ADSCs on chronic
critical limb ischemia: the first adopting intra-muscular injection, the second by intravenous
injection in diabetic patients. The literature regarding different clinical trials [Table 4.]demon‐
strates that ADSCs-based therapies are a concrete opportunity but despite these results,
molecular, cellular e biological features of these cells are still uncertain and it is also unclear if
regenerative therapy is related to their differentiation potential or paracrine activity: indeed,
more appropriate in vivo investigations are necessary.
Pathology Operating methods Condition
Stress urinary after
prostatectomy
peri-urethral injection of autologous ADSCs Report of three
initial cases
Crohn’s fistula injection into rectal mucosa of autologous of ADSCs with
fibrin glue
Phase III
Cirrhosis intrahepatic arterial administration of autologous SVF Phase I
Diabetes I intravenous injection of autologous SVF Phase I/II
Diabetes II autologous SVF Phase I/II
Hypotrophic scars subcutaneous injection of ADSCs Phase III
Chronic critical limb ischemia intra-muscular injection of ADSCs Phase I
Chronic critical limb ischemia
in diabetic patients
intravenous injection of ADSCs Phase I/II
Myocardial infarction intracoronary injection of SVF Phase II/III
Multiple sclerosis intravenous injection of autologous ADSCs Phase I/II
Reumathoid arthritis intrarticular injection of autologous ADSCs Phase III
Table 4. Clinical trials using adipose-derived stem cells (ADSCs) or stromal vascular fraction (SVF).
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6. Tissue engineering
6.1. Adipose derived bio-products
In the past  decade,  preclinical  and translational  efforts  have established the future basis
for  the application of  ADSCs from the bench to the bedside.  Significantly,  ADSCs have
been widely used in  tissue engineering,  organ repair  and gene therapy.  These multipo‐
tent  cells,  have  shown  a  remarkable  plasticity  and  the  ability  to  differentiate  towards
different  cell  lineages  with  similar  yet  enhanced  properties  (their  multipotency  and
proliferative efficiency)  in comparison to bone marrow-derived mesenchymal stem cells.
[3,6-7,21-24,26]  Moreover,  ADSCs also show adjuvant angiogenic  properties  likely related
to  the  secretion  of  vascular  endothelial  growth  factor.  [21]  In  vitro  studies  have  rapid‐
ly increased during the last  decade,  resembling the need to optimize the variables  of  the
differentiation  process  cells  towards  the  desired  lineage.  The  efficient  use  of  biomateri‐
als,  delivery  vehicles  and bioreactors  has  promoted the  development  of  a  large  variety
of  novel  tissue  engineered  products  for  repair  and  regeneration  of  various  tissues  and
organs.  The use of  suitable  animal  models  in an extensive preclinical  literature has also
established the basis  for  successful  stem cell-based therapies that  may implement current
therapeutic  solutions for  several  diseases.  Thus,  a  focus of  most  interest  for  the scientif‐
ic  community is  posed today in the production of  safe and reliable cell  delivery vehicles/
scaffolds useful  in applying ADSCs as a  therapy as well  as  in the development of  novel
suitable  in  vivo  animal  models.  A  large  variety  of  bioengineered  products  have  been
developed by  means  of  selected  differentiating  cultures  of  ADSCs.  [Table  5]  Preclinical
studies  have  experimentally  reported  the  adoption  of  ADSCs  in  order  to  develop  cells
of  mesodermal origin as well  as  cells  of  non-mesodermal lineage such as neural  o neural-
like cells  for  repair  of  neural  traumatic  injuries,  fibroblast  for  reconstruction of  soft  tissue
defects,  tenocytes  or  regenerated  tendon  constructs  for  optimal  musculoskeletal  system
reconstruction,  osteoblasts  for  bone  tissue  replacement,  chondrogenic  lineages  and
cartilage  substitutes  for  implantation,  skeletal  muscle  cells  and  subsequent  myotube-
like formation depicting myogenic  differentiation in vivo in muscular  dystrophy model.
Other  reported  lineages  and  engineered  tissues  that  may  be  obtain  through  selective
differentiation  include  hepatocytes,  pancreatic  endocrine  cells,  cardiomyocytes  and
vascular  endothelial  cells.  [24]  Most  relevant transcription factors  involved in differentia‐
tion  into  adipocytes,  chondrocytes,  myocytes  and  osteocytes  are  well-known.  However,
in addition to specific  differentiation factors,  tridimensional  biomaterials  are  essential  to
address  differentiation  of  ADSCs  to  the  required  cell  type  and  to  use  them  for  tissue-
engineering  purposes.  Among  investigated  effective  scaffolds  and  matrices  we  may
include:  type I  collagen,  hyaluronic,  poly lactic-co-glycolic  acid (PLGA) and silk fibroin-
chitosan.  [26]  Moreover,  the  combination  with  specific  growth  factors  determines  the
overall  outcome of  the applied biopolymer.
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Tissue Cell type Gene Scaffold Result
Bone human ADSCs BMP-2 - heal critical sized femoral
defects in a nude mouse model
ADSCs BMP-2 collagen sponge increase bone induction in SCID
mice





create neo-maxilla in human
Cartilage ADSCs - polyglycolic acid scaffolds exhibit in vitro chondrogenic
characteristics
ADSCs - - improve outcome measures in
osteoarthritis in dogs
Endothelia ADSCs - porous polycaprolactone
(PCL) scaffold
endothelial differentiation
Tendon ADSCs - decellularized human
tendon
recellularize
Nerve ADSCs - hyaluronan membrane
and fibrin meshes
differentiate in glial-like and
neuronal-like cells
Table 5. Synopsis of current approaches in ADSCs and tissue engineering.
Figure 3. Electron microscopy scanning of ADSCs cultured on a Hyaluronic acid-based biomaterial.
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6.1.1. Bio-engineered bone
There is still a clinical need to generate bone for the repair of large osseous defects, since current
strategies are based on non-vascularized bone grafts, suitable only for small defects. As an
alternative, progenitor cells might be implanted on biomaterials and differentiated in vivo
supporting reconstruction of large bone losses. Osteo-inductive factors include vitamin D3,
β-glicerophosphate, acid ascorbic and Bone Morphogenic Proteins (BMPs). [7] Treating ADSCs
with recombinant BMP-2 has shown to stimulate osteogenic differentiation: [27] human
ADSCs overexpressing BMP-2 could heal critical sized femoral defects in a nude mouse model.
Similarly, ADSCs exposed to BMP-2 adenoviral transfection and seeded in collagen sponges
increased bone induction in SCID mice. [27-28] These results suggest that transfected stem cells
can replace the exogenous addition of growth factors when transplanted in a bio-engineered
scaffold. The use of scaffolds is critical in repair of structural tissues such as bone. Deminer‐
alized bone matrix, collagen, PLGA, hydroxyapatite and β-tricalcium phosphate scaffolds
were reported to be suitable for ADSC-derived osteochondral tissue engineering. Most of
clinical trials of osteogenesis in ADSCs rely on murine studies and human trials are based on
very limited reports. The first human case involved transplantation of SVF together with bone
graft to treat calvarial defects [29] and in another case a neo-maxilla has been created using a
β-tricalcium phosphate-filled titanium scaffold associated to cultured ADSCs. [30] Thus,
ADSCs-based osteogenesis is possible, however, more adequate evidence is needed in the
clinical setting.
6.1.2. Bio-engineered cartilage
ADSCs might be used to generate cartilage for clinical use in the treatment of degenerative
joints. The list of potentially useful growth factors for cartilage repair comprises TGFβ, IGF-1,
FGFs, EGF and BMPs, transcription factors as SOX9 and signal transduction molecules such
as SMADs. Several in vitro studies have shown the chondrogenic differentiation of ADSCs
and this feature is confirmed by their ability to generate cartilage in a variety of experimental
models. ADSCs seeded into polyglycolic acid (PGA) scaffolds exhibited in vitro chondrogenic
characteristics and they could synthesized cartilage extracellular matrix. [23] The great
potential of ADSCs in cartilage tissue engineering was also demonstrated in different studies
in vivo. Moreover ADSCs have been used recently for treatment of osteoarthritis in dogs [32]
and rheumatoid arthritis in human. [33] However, given the lack of evidence, it seems likely
that the symptomatic benefits seen in these trials may relate to the anti-inflammatory proper‐
ties of ADSCs rather than to a real chondrogenic differentiation.
6.1.3. ADSCs and vascular/endothelial tissue engineering
The vascularization of regenerated tissues is an important field of research since it allow the
survival of tissue and the differentiated cells. [24] It has been reported that human ADSCs have
the potential for endothelial differentiation and they can participate in blood vessel formation
by means of the secretion of several pro-angiogenic factors, like vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF). [23] This feature makes these cells
suitable for regenerative cell therapy, treatment of ischemic disorders and construction of
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vascularized grafts in one-step procedure, as it has already been performed in many experi‐
ments on animal models. [22] Furthermore, as reminded, the angiogenetic properties of ADSCs
have been already investigated in several clinical trials to treat various diseases.
6.1.4. Bio-engineered tendon
Tendon tissue engineering is relatively unexplored due to the difficulty to maintain in vitro
preservation of tenocyte phenotype: only recently research has demonstrated the fundamental
role of in vitro mechanical stimuli in maintaining the phenotype of tendinous tissues. [34] The
main growth factors inducing tendon differentiation include fibroblast growth factor (FGF),
platelet-derived growth factor-BB (PDGF-BB), epidermal growth factor (EGF), insulin-like
growth factor (IGF)-1 and members of the transforming growth factor-β (TGF-β)/bone
morphogenetic proteins (BMPs) family. Several in vivo and in vitro studies have showed the
ability of ADSCs to differentiate in tenocytes under specific stimuli and under biomechanical
force. [34] Furthermore, recent experiments have focused on the possibility of re-cellularize by
means of seeded ADSCs a decellularized human tendon. [35] Thus, an integration of ADSCs,
growth factors, mechanical stimuli and biopolymers may provide a solution for the treatment
of difficult tendon injuries
6.1.5. ADSCs and neuronal tissue-engineering
Incubation of ADSCs under neuro-inductive conditions (culture medium containing EGF,
FGF, NGF and BDNF) has shown the potential to form neurospheres expressing neurospecific
markers, including nestin¸ βIII tubulin, S100 and glial fibrillar acidic protein (GFAP). [36]
Moreover, seeding of these neurospheres in different scaffolds (hyaluronan based membranes
and fibrin glue meshes) demonstrated further differentiation in glial-like and neuronal-like
cells. [37] Although these are only preliminary researches, these promising results are of
significant clinical interest. ADSCs-induced neural cells may provide beneficial therapeutic
effects in treatment of injuries occurring to both the peripheral and central nervous systems
such as in the treatment of neurodegenerative states, including Parkinson’s disease, Hungtin‐
ton’s disease, multiple sclerosis and Alzheimer’s disease.
7. Prospectives
Regenerative medicine is an evolving field of research and therapeutics in which adipose tissue
and ADSCs hold great promise for translational research and future clinical applications in
many fields of tissue regeneration with a wide range of potential clinical implications. In the
past decade, preclinical data from in vitro studies and pre-clinical animal models has been
provided on the reproducibility, safety and efficacy of ADSCs in tissue regeneration or tissue
engineering, supporting their use in clinical applications and establishing the basis for a
translational application in the bedside: consistently, recent preliminary clinical trials have
confirmed positive outcomes. The enhancing effect of ADSCs on autologous repair might
enable better clinical outcomes and play a relevant role in healing acute and chronic tissue
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damage. Thus, more accurate information regarding optimal management and methods to
promote differentiation lineages (among which differentiation factors, cell scaffolds, cell
culture conditions) are strongly required. Further translational research, adequate clinical
investigation and novel strategies should be promoted and designed to overcome current
limitations, encourage future therapeutic implementation and face challenges posed by
regenerative medicine.
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